Investing.com -- Boston Scientific (NYSE:BSX) reported fiscal Q4 2024 results that surpassed analyst expectations. The company's shares swung between gains and losses in premarket trading Wednesday.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges ...